DR. BIJAL J MODI M.D. NPI 1285684944

NPI Details

DR. Bijal J Modi, M.D. is a hematology and oncology internal medicine in Dallas, TX with 26 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Bijal J Modi, M.D. NPI is 1285684944. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: RUTGERS NEW JERSEY MEDICAL SCHOOL
Graduation Year:2000

The provider's business location address is:

8196 WALNUT HILL LN STE 100
DALLAS, TX
ZIP 75231-001
Phone: (214) 739-4175
Fax: (214) 346-3541

The NPI 1285684944 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Ferritin (blood protein) level (HCPCS:82728)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Unclassified drugs (HCPCS:J3490)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection of drug or substance into vein (HCPCS:96374)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, lorazepam, 2 mg (HCPCS:J2060)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Drawing of blood for a medical problem (HCPCS:99195)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)

The enumeration date for this NPI number is 5/11/2006 and was last updated on 4/24/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.